This week in therapeutics




Licensing status

Publication and contact information


Alzheimer's disease (AD)

Histone deacetylase 6 (HDAC6)

In vitro and mouse studies identified HDAC6 inhibitors that could help treat AD. In human neuronal cells, hydroxamic acid-based quinazoline-4-one derivatives that specifically inhibited HDAC6 induced neurite outgrowth and synaptic activity. In mice with hippocampal b-amyloid (Ab) aggregation, intraperitoneal injection of either of two different inhibitors decreased learning impairments compared with vehicle injection. Ongoing studies include lead optimization of the inhibitor series.
Acetylon Pharmaceuticals Inc. has the HDAC6 inhibitor ACY-1215 in Phase I/II testing to treat multiple myeloma (MM).
At least two other companies have HDAC6 inhibitors in preclinical development to treat cancer and inflammation.

SciBX 6(35); doi:10.1038/scibx.2013.967
Published online Sept. 12, 2013

Patent application filed; licensed by AnnJi Pharmaceutical Co.; unavailable for licensing

Yu, C.-W. et al. J. Med. Chem.; published online Aug. 1, 2013;
Contact: Ji-Wang Chern, National Taiwan University, Taipei, Taiwan